TRACON Pharmaceuticals, which is developing antibodies to treat cancer, AMD and fibrotic diseases, filed on Monday with the SEC to raise up to $58 million in an initial public offering. The San Diego, CA-based company, which was founded in 2004, plans to list on the NASDAQ under the symbol TCON. TRACON Pharmaceuticals initially filed confidentially on August 8, 2014. Wells Fargo Securities and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
